Financial PerformanceLast quarter, Viridian reported earnings per share of -$1.35 versus the consensus of -$0.99 and the estimate of -$0.91, primarily due to severance costs for its outgoing CEO.
Market CompetitionWith competitor Amgen advancing their own subcutaneous Tepezza program, there is increased pressure on VRDN to execute effectively in a competitive market.
Market SentimentViridian's stock is faced with a high short interest, indicating that a significant portion of the market may be betting against the company's success.